Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 26, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) held through employee benefit plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transaction details and does not contain a financial performance summary.
Material Changes
- Employee Share Option Plan: On April 22, 2005, the GlaxoSmithKline Employee Trust transferred 1,933 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Savings Plan: On April 22, 2005, the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan increased from 18,260,668 to 18,299,091 due to fund movements.
- Transaction Price: The average price for the ADR movement in the US Retirement Savings Plan was $47.12.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses exclusively on regulatory disclosure regarding director interests in employee trusts and funds.
Investor Verification Points
- Verify the impact of the 1,933 share transfer on the total outstanding share count.
- Confirm the current holdings of the US Retirement Savings Plan (18,299,091 ADRs) and its valuation at the reported average price of $47.12.
- Identify the specific directors with interests in these plans: Dr. J-P Garnier, Dr. T Yamada, and Mr. J S Heslop.